Table 2 PARP1 genotypes and disease-free survival.

From: Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy

Variables

Patients (%)

5 y DFS(%)

Crude

Adjusted

HR (95% CI)

P

HR (95% CI)

P

Rs1136410

TT

94(34.6)

69.4

1(Ref)

 

1(Ref)

 

TC

134(49.3)

73.3

0.791(0.463–1.351)

0.391

0.891 (0.516–1.537)

0.678

CC

44(16.1)

74.2

0.895(0.440–1.819)

0.759

0.877(0.428–1.796)

0.719

rs11801168

TT

7(2.6)

64.3

1(Ref)

 

1(Ref)

 

TC

68(25.0)

76.7

0.885(0.202–3.881)

0.872

1.070(0.240–4.772)

0.929

CC

197(72.4)

71.4

0.996(0.241–4.109)

0.995

1.255(0.296–5.322)

0.758

rs12568297

GG

226(83.1)

72.4

1(Ref)

 

1(Ref)

 

GC

41(15.1)

75.1

1.085(0.552–2.133)

0.814

1.020(0.513–2.027)

0.956

CC

5(1.8)

53.3

1.511(0.366–6.229)

0.568

1.531(0.351–6.680)

0.571

Rs6664761

TT

33(12.1)

68.3

1(Ref)

 

1(Ref)

 

TC

119(43.8)

74.6

0.537(0.261–1.102)

0.090

0.564(0.272–1.171)

0.124

CC

120(44.1)

70.5

0.712(0.358–1.417)

0.333

0.755(0.376–1.516)

0.429

Rs7531668

TT

163(59.9)

69.2

1(Ref)

 

1(Ref)

 

TA

78(28.7)

79.3

0.594(0.319–1.108)

0.102

0.526(0.280–0.990)

0.046

AA

31(11.4)

69.6

1.335(0.669–2.662)

0.412

1.190(0.588–2.406)

0.629

  1. Abbreviations: DFS, disease free survival; OS, overall survival; HR, hazard ratios; CI, confidence interval; Ref, reference.